Protagonist Therapeutics (PTGX) IPO Opened Flat

August 11, 2016 11:29 AM EDT
Get Alerts PTGX Hot Sheet
Trade PTGX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Today's IPO for Protagonist Therapeutics (NASDAQ: PTGX) opened for trading earlier at $12 after pricing 7,500,000 shares of common stock at a price to the public of $12 per share, the middle of the expected $11 - $13 range.

Leerink Partners LLC, Barclays Capital Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

BMO Capital, Barclays, IPO

Add Your Comment